Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641334 | 0.80 | ALDH1A1 (0.48) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL641264 | 0.73 | ALDH1A1 (0.45) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL642024 | 0.72 | ALDH1A1 (0.43) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL640097 | 0.70 | MAPT (0.50) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL639781 | 0.69 | ALDH1A1 (0.42) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL5465985 | 0.68 | ALDH1A1 (0.60) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL2953452 | 0.65 | ALDH1A1 (0.77) | ALOX15TSHRALDH1A1GAAMEN1 | |
| SCHEMBL639890 | 0.64 | MAPT (0.49) | MAPTSMN1; SMN2ALOX15MAPK1TSHR | |
| SCHEMBL14183920 | 0.64 | L3MBTL1 (0.71) | MAPTSMN1; SMN2ALOX15TSHRALDH1A1 | |
| SCHEMBL2961832 | 0.63 | ALDH1A1 (1.00) | MAPTSMN1; SMN2ALOX15MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | MAPT 4368/4885SMN1; SMN2 3474/4885ALOX15 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.